Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its
incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer …

Purpose We report CNS efficacy of osimertinib versus standard epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with untreated EGFR-mutated …

Introduction Afatinib is an effective first-line treatment in patients with epidermal growth factor
receptor (EGFR)-mutated non–small-cell lung cancer (NSCLC) and has shown activity in …

Purpose Several cases have been reported in which central nervous system (CNS)
metastases of non-small cell lung cancer (NSCLC) resistant to gefitinib were improved by …

BACKGROUND: The discovery of distinct subsets of nonsmall cell lung cancer (NSCLC)
characterized by activation of driver oncogenes has greatly affected personalized therapy. It …

BACKGROUND: There is no published overview of epidermal growth factor receptor (EGFR)
tyrosine kinase inhibitor (TKI) failure modes in advanced non-small-cell lung cancer …

Objectives Osimertinib has been reported to be effective against central nervous system
(CNS) metastasis from activating EGFR mutation-positive NSCLC. Nevertheless, the true …

Purpose: Given that osimertinib is the only approved third-generation EGFR-TKI against
EGFR activating and resistant T790M mutated non–small cell lung cancer (NSCLC) …

The brain is a major sanctuary site for metastatic cancer cells that evade systemic therapies.
Through pre-clinical pharmacological, biological, and molecular studies, we characterize the …